Melatonin alters behavior and cAMP levels in nucleus accumbens induced by cocaine treatment

Brain Research

Volumn 956, Issue 2, 2002, Pages 323-331

  Zhdanova, Irina V ^a,b   Giorgetti, Marco ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anxiety; cAMP; Cocaine; Melatonin; Nucleus accumbens; Withdrawal

Indexed keywords

COCAINE; CYCLIC AMP; MELATONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; ATTENUATION; BEHAVIOR; DOSE RESPONSE; DRINKING; DRUG EFFECT; DRUG SELF ADMINISTRATION; DRUG WITHDRAWAL; LOW DRUG DOSE; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; COCAINE; CYCLIC AMP; DOPAMINE UPTAKE INHIBITORS; MALE; MELATONIN; NUCLEUS ACCUMBENS; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 0037195575     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(02)03565-5     Document Type: Article

References (76)

1. Alexiuk N.A., Vriend J.P. Effects of daily afternoon melatonin administration on monoamine accumulation in median eminence and striatum of ovariectomized hamsters receiving pargyline. Neuroendocrinology. 54:(1):1991;55-61.
2. Alexiuk N.A., Vriend J.P. Melatonin reduces dopamine content in the neurointermediate lobe of male Syrian hamsters. Brain Res. Bull. 32:(4):1993;433-436.
3. Arendt J., Middleton B., Stone B., Skene D. Complex effects of melatonin: evidence for photoperiodic responses in humans? Sleep. 22:(5):1999;625-635.
4. Arushanian E.B., Chernysheva E.M. The comparative effect of melatonin and diazepam on shifts in the anxiety-phobia status of rats evoked by damage to the amygdala. Eksp. Klin. Farmakol. 60:(1):1997;87-91.
5. Attia A.M., Mostafa M.H., Richardson B.A., Reiter R.J. Changes in nocturnal pineal indoleamine metabolism in rats treated with parathion are prevented by beta-adrenergic antagonist administration. Toxicology. 97:(1-3):1995;183-189.
6. Basso A.M., Spina M., Rivier J., Vale W., Koob G.F. Corticotropin-releasing factor antagonist attenuates the 'anxiogenic-like' effect in the defensive burying paradigm but not in the elevated plus-maze following chronic cocaine in rats. Psychopharmacology (Berl.). 145:(1):1999;21-30.
7. Baturin V.A., Manvelian E.A. The effect of melatonin on rat behavior in a conflict situation. Eksp. Klin. Farmakol. 58:(6):1995;17-18.
8. Blanchard D.C., Blanchard R.J. Cocaine potentiates defensive behaviors related to fear and anxiety. Neurosci. Biobehav. Rev. 23:(7):1999;981-999.
9. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
10. Burchfield D.J., Peters A.J., Abrams R.M., Phillips D. Fetal behavioral state patterns during and after prolonged exposure to cocaine in sheep. Am. J. Obstet. Gynecol. 172:1995;1223-1228.
11. DeVries A.C., Pert A. Conditioned increases in anxiogenic-like behavior following exposure to contextual stimuli associated with cocaine are mediated by corticotropin-releasing factor. Psychopharmacology (Berl.). 137:(4):1998;333-340.
12. Dubocovich M.L. Melatonin is a potent modulator of dopamine release in the retina. Nature. 4:(306 (5945)):1984;782-4-8.
13. Escames G., Acuna Castroviejo D., Vives F. Melatonin-dopamine interaction in the striatal projection area of sensorimotor cortex in the rat. Neuroreport. 7:(2):1996;597-600.
14. Estroff T.W., Schwartz R.H., Hoffman N.G. Adolescent cocaine abuse: addictive potential, behavioral and psychiatric effects. Clin. Pediatr. 28:1989;550-555.
15. Fontana D.J., Commissaris R.L. Effects of cocaine on conflict behavior in the rat. Life Sci. 45:(9):1989;819-827.
16. Gaffori O., Van Ree J.M. Serotonin and antidepressant drugs antagonize melatonin-induced behavioral changes after injection into the nucleus accumbens of rats. Neuropharmacology. 24:(3):1985;237-244.
17. Gawin F.H., Kleber H.D. Abstinence symptomatology and psychiatric diagnosis in cocaine abusers. Clinical observations. Arch. Gen. Psychiatry. 43:(2):1986;107-113.
18. Gingras J.L., Feibel J.B., Dalley L.B., Muelenaer A., Knight C.G. Maternal polydrug use including cocaine and postnatal infant sleep architecture: preliminary observations and implications for respiratory control and behavior. Early Hum. Dev. 43:(3):1995;197-204.
19. Giorgetti M., Zhdanova I.V. Chronic cocaine treatment induces dysregulation in the circadian pattern of rats' feeding behavior. Brain Res. 877:(2):2001;170-175.
20. Golombek D.A., Martini M., Cardinali D.P. Melatonin as an anxiolytic in rats: time dependence and interaction with the central GABAergic system. Eur. J. Pharmacol. 237:(2-3):1993;231-236.
21. Golombek D.A., Pevet P., Cardinali D.P. Melatonin effects on behavior: possible mediation by the central GABAergic system. Neurosci. Biobehav. Rev. 20:(3):1996;403-412.
22. Guardiola-Lemaitre B., Lenegre A., Porsolt R.D. Combined effects of diazepam and melatonin in two tests for anxiolytic activity in the mouse. Pharmacol. Biochem. Behav. 41:(2):1992;405-408.
23. Hamdi A. Melatonin administration increases the affinity of D2 dopamine receptors in the rat striatum. Life Sci. 63:(23):1998;2115-2120.
24. Harris G.C., Aston-Jones G. Beta-adrenergic antagonists attenuate withdrawal anxiety in cocaine- and morphine-dependent rats. Psychopharmacology (Berl.). 113:(1):1993;131-136.
25. Harris G.C., Aston-Jones G. Beta-adrenergic antagonists attenuate somatic and aversive signs of opiate withdrawal. Neuropsychopharmacology. 9:(4):1993;303-311.
26. Harris G.C., Aston-Jones G. Involvement of D2 dopamine receptors in the nucleus accumbens in the opiate withdrawal syndrome. Nature. 371:(6493):1994;155-157.
27. Hyman S.E. Shaking out the cause of addiction. Science. 273:(5275):1996;611-612.
28. Iijima Y., Shinoda M., Kuribara H., Asami T., Uchihashi Y. Evaluation of acute and sub-acute effects of cocaine by means of circadian variation in wheel-running and drinking in mice. Nihon Shinkei Seishin Yakurigaku Zasshi. 15:(4):1995;315-321.
29. Iredale P.A., Alvaro J.D., Lee Y., Terwilliger R., Chen Y.L., Duman R.S. Role of corticotropin-releasing factor receptor-1 in opiate withdrawal. J. Neurochem. 74:(1):2000;199-208.
30. Koek W., Patoiseau J.F., Assie M.B., Cosi C., Kleven M.S., Dupont-Passelaigue E., Carilla-Durand E., Palmier C., Valentin J.P., John G., Pauwels P.J., Tarayre J.P., Colpaert F.C. F 11440, a potent, selective, high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential. J. Pharmacol. Exp. Ther. 287:(1):1998;267-283.
31. Koob G.F., Caine B., Markou A., Pulvirenti L., Weiss F. Role for the mesocortical dopamine system in the motivating effects of cocaine. NIDA Res. Monogr. 145:1994;1-18.
32. Kopp C., Vogel E., Rettori M.C., Delagrange P., Guardiola-Lemaitre B., Misslin R. Effects of melatonin on neophobic responses in different strains of mice. Pharmacol. Biochem. Behav. 63:(4):1999;521-526.
33. Kreek M.J., Koob G.F. Drug dependence: stress and dysregulation of brain reward pathways. Drug Alcohol Depend. 51:(1-2):1998;23-47.
34. Leshner A.I., Koob G.F. Drugs of abuse and the brain. Proc. Assoc. Am. Physicians. 111:(2):1999;99-108.
35. Markou A., Hauger R.L., Koob G.F. Desmethylimipramine attenuates cocaine withdrawal in rats. Psychopharmacology (Berl.). 109:(3):1992;305-314.
36. Murakami M., Tominaga S., Watanabe K. Effects of anesthesia on the levels of cyclic nucleotides in rat brain regions. Nippon Yakurigaku Zasshi. 78:(6):1981;579-587.
37. Nestler E.J. Molecular mechanisms of drug addiction. J. Neurosci. 12:(7):1992;2439-2450.
38. Nestler E.J., Alreja M., Aghajanian G.K. Molecular control of locus coeruleus neurotransmission. Biol. Psychiatry. 46:(9):1999;1131-1139.
39. Nestler E.J., Terwilliger R.Z., Walker J.R., Sevarino K.A., Duman R.S. Chronic cocaine treatment decreases levels of the G protein subunits Gi alpha and Go alpha in discrete regions of rat brain. J. Neurochem. 55:(3):1990;1079-1082.
40. Neville K., McNaughton N. Anxiolytic-like action of melatonin on acquisition but not performance of DRL. Pharmacol. Biochem. Behav. 24:(6):1986;1497-1502.
41. Palkovits M. Isolated removal of hypothalamic or other brain nuclei of the rat. Brain Res. 59:1973;449-450.
42. Palmer G.C., Jones D.J., Medina M.A., Stavinoha W.B. Anticonvulsant drug actions on in vitro and in vivo levels of cyclic AMP in the mouse brain. Epilepsia. 20:(2):1979;95-104.
43. Pierrefiche G., Zerbib R., Laborit H. Anxiolytic activity of melatonin in mice: involvement of benzodiazepine receptors. Res. Commun. Chem. Pathol. Pharmacol. 82:(2):1993;131-142.
44. Pulvirenti L., Koob G.F. Dopamine receptor agonists, partial agonists and psychostimulant addiction. Trends Pharmacol. Sci. 15:(10):1994;374-379.
45. Rassnick S., Heinrichs S.C., Britton K.T., Koob G.F. Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal. Brain Res. 605:(1):1993;25-32.
46. Redman J.R. Circadian entrainment and phase shifting in mammals with melatonin. J. Biol. Rhythms. 12:(6):1997;581-587.
47. Reppert S.M. Melatonin receptors: molecular biology of a new family of G protein-coupled receptors. J. Biol. Rhythms. 12:1997;528-531.
48. Resnick R.B., Resnick E.B. Cocaine abuse and its treatment. Psychiatr. Clin. North. Am. 7:(4):1984;713-728.
49. Sarnyai Z., Biro E., Gardi J., Vecsernyes M., Julesz J., Telegdy G. Brain corticotropin-releasing factor mediates 'anxiety-like' behavior induced by cocaine withdrawal in rats. Brain Res. 675:(1-2):1995;89-97.
50. Schneider H.H. Brain cAMP response to phosphodiesterase inhibitors in rats killed by microwave irradiation or decapitation. Biochem. Pharmacol. 33:(10):1984;1690-1693.
51. Self D.W., Nestler E.J. Molecular mechanisms of drug reinforcement and addiction. Annu. Rev. Neurosci. 18:1995;463-495.
52. Self D.W., Nestler E.J. Relapse to drug-seeking: neural and molecular mechanisms. Drug Alcohol Depend. 51:(1-2):1998;49-60.
53. 2-like dopamine receptor agonists. Science. 271:1996;1586-1589.
54. Self D.W., Genova L.M., Hope B.T., Barnhart W.J., Spencer J.J., Nestler E.J. Involvement of cAMP-dependent protein kinase in the nucleus accumbens in cocaine self-administration and relapse of cocaine-seeking behavior. J. Neurosci. 18:(5):1998;1848-1859.
55. Sircar R. Effect of melatonin on cocaine-induced behavioral sensitization. Brain Res. 857:(1-2):2000;259-295.
56. Spear L.P., Brake S.C. Periadolescence: age-dependent behavior and psychopharmacological responsivity in rats. Dev. Psychobiol. 16:(2):1983;83-109.
57. Striplin C.D., Kalivas P.W. Correlation between behavioral sensitization to cocaine and G protein ADP-ribosylation in the ventral tegmental area. Brain Res. 579:(2):1992;181-186.
58. Sugden D. Psychopharmacological effects of melatonin in mouse and rat. J. Pharmacol. Exp. Ther. 227:(3):1983;587-591.
59. 125I)iodomelatonin binding affinity of melatonin analogues. Psychopharmacology (Berl.). 117:(3):1995;364-370.
60. Terwilliger R.Z., Beitner-Johnson D., Sevarino K.A., Crain S.M., Nestler E.J. A general role for adaptations in G-proteins and the cyclic AMP system in mediating the chronic actions of morphine and cocaine on neuronal function. Brain Res. 548:(1-2):1991;100-110.
61. Tolliver B.K., Ho L.B., Reid M.S., Berger S.P. Evidence for involvement of ventral tegmental area cyclic AMP systems in behavioral sensitization to psychostimulants. J. Pharmacol. Exp. Ther. 278:(1):1996;411-420.
62. Uz T., Javaid J.I., Manev H. Circadian differences in behavioral sensitization to cocaine: putative role of arylalkylamine N-acetyltransferase. Life Sci. 70:(25):2002;3069-3075.
63. Weaver D.R. Melatonin and circadian rhythmicity in vertebrates: physiological role and pharmacological effects. Turek F.W., Lee P.C., Regulation of Sleep and Circadian Rhythms. 1999;197-247 Marcel Dekker, New York.
64. Weiss F., Markou A., Lorang M.T., Koob G.F. Basal extracellular dopamine levels in the nucleus accumbens are decreased during cocaine withdrawal after unlimited-access self-administration. Brain Res. 593:(2):1992;314.
65. Withers N.W., Pulvirenti L., Koob G.F., Gillin J.C. Cocaine abuse and dependence. J. Clin. Psychopharmacol. 15:(1):1995;63-78.
66. Yang X.M., Gorman A.L., Dunn A.J., Goeders N.E. Anxiogenic effects of acute and chronic cocaine administration: neurochemical and behavioral studies. Pharmacol. Biochem. Behav. 41:(3):1992;643-650.
67. Zhdanova I.V. Role of melatonin in sleep and sleep disorders. Culebras A., Sleep Disorders and Neurological Disease. 1999;137-157 Marcel Dekker, New York.
68. Zhdanova I.V., Piotrovskaya V.R. Melatonin reduces symptoms of acute nicotine withdrawal in humans. Pharmacol. Biochem. Behav. 67:2000;131-135.
69. Zhdanova I.V., Lynch H.J., Wurtman R.J. Melatonin: a sleep-promoting hormone. Sleep. 20:(10):1997;899-907.
70. Zhdanova I.V., Geiger D.A., Schwagerl A.L., Leclair O.U., Taylor J.A., Rosene D.L., Moss M.B., Madras B.K. Melatonin promotes sleep in three species of diurnal non-human primates. Physiol. Behav. 75:2002;523-529.
71. Zhdanova I.V., Wang S., Leclair O.U., Danilova N. Melatonin promotes sleep-like behavior in zebrafish. Brain Res. 903:(1-2):2001;263-268.
72. Zhdanova I.V., Wurtman R.J., Morabito C., Piotrovska V.R., Lynch H.J. Effects of low oral doses of melatonin, given 2-4 h before habitual bedtime, on sleep in normal young humans. Sleep. 19:(5):1996;423-431.
73. Zhdanova I.V., Cantor M.L., Leclair O.U., Kartashov A., Wurtman R.J. Behavioral effects of melatonin treatment in non-human primates. Sleep Res. Online. 1:(3):1998;114-118.
74. Zisapel N., Laudon M. Inhibition by melatonin of dopamine release from rat hypothalamus: regulation of calcium entry. Brain Res. 272:(2):1983;378-381.
75. Zisapel N., Egozi Y., Laudon M. Inhibition of dopamine release by melatonin: regional distribution in the rat brain. Brain Res. 246:(1):1982;161-163.
76. Zisapel N., Egozi Y., Laudon M. Circadian variations in the inhibition of dopamine release from adult and newborn rat hypothalamus by melatonin. Neuroendocrinology. 40:(2):1985;102-108.